Winter is Coming and so is Arya Sciences Acquisition Corp.
Arya Sciences Acquisition Corp. filed for a $125 million SPAC IPO today, with a focus on the healthcare, and more specifically, the life sciences and medical technology sectors. Additionally, Perceptive Advisors, one of the most well known life sciences hedge funds, is acting as sponsor.
Arya Sciences is being led by Joseph Edelman, the founder of Perceptive Advisors, as Chairman, and Adam Stone, who is the Chief Investment Officer of Perceptive, as CEO and Director. If you’re going to be looking in the healthcare space, it’s hard to argue with wanting Perceptive involved. Perceptive has over $5 billion in assets under management focused exclusively on the healthcare industry so clearly they have some understanding of the sector.
Additionally, Perceptive Advisors will be sponsoring this SPAC via it’s affiliate – Arya Sciences Holdings, and has indicated an interest in purchasing up to $25 million of shares at business combination. However, an “indication of interest” is sort of like the Coke Zero of backstops. Tastes like Coke, but without any of the “sugar”. I.e., they say they’re interested, but it doesn’t hold a lot of weight.
A summary of terms has been provided below, but you can review the the profile page with management bios here.
Arya Sciences Summary of Terms:
- Focus: Healthcare – Life Sciences/Med Tech
- Size: $125 million
- 100.0% held in trust ($10.00 per share)
- $10.00 unit comprised of one share of Common Stock + 1/2 of a full Warrant
- Warrant call for redemption trigger: equals or exceeds $18.00 (cash or cashless exercise)
- 24 months to complete an acquisition
- Limitation on Redemption Rights: 15%
- At-risk Capital: $5.44 million (5,437,500 warrants at $1.00)
- Indication of Interest:
- Arya Science Holdings (an affiliate of Perceptive), the Sponsor, has indicated an interest in purchasing up to $25 million of shares at combination
- Underwriter fees: 2.75% + 3.25% deferred.
Jefferies is sole book-running manager and Chardan is lead manager.
Kirkland & Ellis LLP and Skadden, Arps, Slate, Meagher & Flom LLP are Issuer’s Counsel and Underwriter’s Counsel, respectively.
Once again, the November 2024 corporate actions continues the trend of SPAC teams seeking additional extensions beyond their first one as they work to close their combinations with the remaining funds after redemptions. However, both announcements and completion vote-type corporate actions events were unusually light this month. Extension Votes In November, there were a whopping...
Future Vision II (NASDAQ:FVNNU) has entered into a definitive agreement to combine with adtech firm Viwo at an equity value of $100 million. Beijing-based Viwo provides AI-enabled targeting technology for marketers and brands in China. The combined company is expected to trade on the Nasdaq once the deal is completed by the end of the...
At the SPAC of Dawn The SPAC market could be primed to wake up from its Turkey Day slumber with a bang this week as both Shepherd Ave (NASDAQ:SPHAU) and Tavia (NASDAQ:TAVIU) have lined up to IPO and five more SPACs have scheduled votes. Late Friday also saw the Future Vision II (NASDAQ:FVNNU) announce a...
Terms Tracker for the Week Ending November 29, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This was a shortened holiday week, but SPACs still managed to put through a number of filings, which should usher in a busy first half...
Range Capital Acqusition Corp. (NASDAQ:RANGU) has filed to launch a $100 million SPAC with a broad approach, but with expertise in natural resources. The vehicle becomes the fourth SPAC that underwriter EarlyBirdCapital has put its name on so far this year, but it bears some different features than the rest of its 2024 slate. EarlyBirdCapital...